NCT03214146View on ClinicalTrials.gov

Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS

PHASE1UnknownINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

March 25, 2019

Study Completion Date

October 31, 2021

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

HYNRCS-Allo inj

The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.

Trial Locations (1)

133-792

Hanyang University Seoul Hospital, Cell Therapy Center for Neurologic Disorders, Seoul

Sponsors

Collaborators (1)

Corestemchemon, Inc.
All Listed Sponsors
collaborator

Corestemchemon, Inc.

INDUSTRY

lead

Hanyang University Seoul Hospital

OTHER

NCT03214146 - Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS | Biotech Hunter | Biotech Hunter